KalVista Pharmaceuticals (KALV)
(Delayed Data from NSDQ)
$14.47 USD
-0.92 (-5.98%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $14.49 +0.02 (0.14%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Brokerage Reports
0 items in cart
KalVista Pharmaceuticals, Inc. [KALV]
Reports for Purchase
Showing records 101 - 106 ( 106 total )
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
First HAE Candidate Unveiled; Reiterate Buy - Raising PT to $22
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare - Spotlight on HAE: Takeaways From Our KOL Discussion
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
The Force Is Strong with This One; Initiating with Buy - $20 PT
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
The Force Is Strong with This One; Initiating with Buy - $20 PT
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.